ChemoCentryx
ChemoCentryx's Overview
ChemoCentryx, Inc. was a biopharmaceutical company focused on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer. Its research centered on chemokine-based biology, culminating in the development of its flagship product, TAVNEOS® (avacopan), a treatment for ANCA-associated vasculitis. In October 2022, ChemoCentryx was acquired by Amgen for approximately $3.7 billion, integrating its pipeline and TAVNEOS® into Amgen's inflammation portfolio.
Where is ChemoCentryx's Headquarters?
HQ Function
This facility served as the main center for ChemoCentryx's research and development, clinical trial management, and corporate administrative operations before its acquisition.
Notable Features:
The headquarters likely included specialized laboratory facilities for drug discovery and development, alongside modern office spaces designed to foster collaboration and innovation.
Work Culture:
The work culture at ChemoCentryx was reportedly driven by scientific innovation, a commitment to addressing unmet patient needs, and a collaborative environment focused on advancing novel therapies.
HQ Significance:
The San Carlos headquarters was crucial for ChemoCentryx's operations, including the development and initial commercialization efforts for TAVNEOS®, and its location provided access to a rich talent pool and biotech ecosystem.
Values Reflected in HQ: The headquarters reflected ChemoCentryx's dedication to scientific excellence, pioneering research in chemokine biology, and a patient-first approach in tackling complex diseases.
Location:
Before being acquired by Amgen, ChemoCentryx established a global presence primarily through its multi-national clinical trials for its drug candidates. For its lead product, TAVNEOS® (avacopan), it forged strategic commercialization partnerships to reach patients in key international markets, including Europe, Japan, and Canada, while direct US commercialization was handled internally. Its R&D and strategic oversight remained U.S.-based. Post-acquisition, its programs and reach are now part of Amgen's global operational footprint.
Street Address:
835 Industrial Road, Suite 600
City:
San Carlos
State/Province:
CA
Country:
USA
ChemoCentryx's Global Presence
Primarily centralized operations in San Carlos, CA
Address: N/A
International activities, such as clinical trials and commercial partnerships (e.g., with Vifor Pharma for TAVNEOS® in Europe and Japan), were managed from the US headquarters or through its partners, rather than dedicated ChemoCentryx international offices.
Buying Intent Signals for ChemoCentryx
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of ChemoCentryx
As of April 2025, ChemoCentryx' leadership includes:
Investors of ChemoCentryx
ChemoCentryx has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
The most significant executive changes for ChemoCentryx as an independent entity in the 12 months prior to its acquisition in October 2022 revolved around the transition of its leadership team following the Amgen takeover. Key executives departed their roles as ChemoCentryx was integrated into Amgen. No major new external executive hires to the independent ChemoCentryx leadership team were publicly announced during this final period.
Departures
Technology (Tech Stack) used by ChemoCentryx
Discover the tools ChemoCentryx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
ChemoCentryx Email Formats and Examples
Prior to its acquisition by Amgen in October 2022, ChemoCentryx, Inc. utilized corporate email addresses associated with its domain. The formats listed below are based on common patterns and publicly available information for ChemoCentryx as an independent company and are for historical reference, as these email addresses are no longer active for former employees.
Commonly used formats were likely [first_initial][last]@chemocentryx.com (e.g., jdoe@chemocentryx.com) or [first].[last]@chemocentryx.com (e.g., jane.doe@chemocentryx.com). Data suggests flast@chemocentryx.com was a prevalent pattern.
Format
tsmith@chemocentryx.com
Example
70%
Success rate
News and media
Amgen Newsroom • October 20, 2022
Amgen Completes Acquisition of ChemoCentryx, Inc.
Amgen announced it successfully completed its acquisition of ChemoCentryx for $52 per share in cash, totaling an approximate enterprise value of $3.7 billion. This acquisition brought TAVNEOS® (avacopan), a first-in-class medicine for ANCA-associated vasculitis, into Amgen's portfolio, enhancing its inflammation and nephrology franchises....more
Fierce Pharma (reporting on FDA/ChemoCentryx) • October 8, 2021
ChemoCentryx (CCXI) FDA Approval of TAVNEOS™ (avacopan) for ANCA-Associated Vasculitis
The U.S. Food and Drug Administration (FDA) granted approval for ChemoCentryx's TAVNEOS™ (avacopan), an oral selective complement 5a receptor inhibitor, as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. This approval was a major achievement for ChemoCentryx, offering a new therapeutic option for this rare autoimmune disease....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including ChemoCentryx, are just a search away.